Prospects for the Use of Antibody-Drug Conjugates in Cancer Therapy
- 6 April 2025
- journal article
- review article
- Published by Pleiades Publishing Ltd in Russian Journal of Bioorganic Chemistry
- Vol. 51 (2) , 556-573
Abstract
Today, cancer continues to be one of the most dangerous diseases, annually causing the deaths of more than 9 million people in the world. Therefore, new and more effective methods of cancer therapy are in demand. As monoclonal antibody-based immunotherapy has already shown its effectiveness, antibody-drug conjugates (ADC), one of its successful variants, have significant and not yet fully realized potential. ADCs are monoclonal antibodies bound to cytotoxic drugs through linkers. In many clinical trials and already in standard clinical practice, ADCs have demonstrated significant advantages over the combination therapy with unmodified antibodies and chemotherapeutic drugs. Due to new achievements in the field of molecular immunology and biotechnology, the potential of ADCs is assessed as a breakthrough, which will allow ADCs to become the most sought-after anticancer drugs in the coming years. Owing to ADCs it has become possible to deliver drugs to tumor cells in a targeted manner without significant toxic effects on healthy tissues and organs. To date, 15 ADC drugs have been approved worldwide for use in clinic, and more than a hundred more drugs of this class are at various stages of clinical trials. At the same time, ADC therapy is associated with certain side effects and limited efficacy. Therefore there is a need to develop more advanced conjugates. This review describes the history of the development of ADC as a therapeutic class of molecules, their structure, targets, and mechanism of action. It also outlines the prospects and directions for further development of ADCs.Keywords
This publication has 87 references indexed in Scilit:
- Unlocking the potential of bispecific ADCs for targeted cancer therapyFrontiers of Medicine, 2024
- Economics of Antibody Drug Conjugates (ADCs): Innovation, Investment and Market DynamicsCurrent Oncology Reports, 2024
- Antibody–drug conjugates: Recent advances in payloadsActa Pharmaceutica Sinica B, 2023
- Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050JAMA Oncology, 2023
- Antibody variable region engineering for improving cancer immunotherapyCancer Communications, 2022
- Antibody–drug conjugates: Recent advances in linker chemistryActa Pharmaceutica Sinica B, 2021
- Venetoclax-based therapies for acute myeloid leukemiaBest Practice & Research Clinical Haematology, 2019
- Current progress in innovative engineered antibodiesProtein & Cell, 2017
- Current ADC Linker ChemistryPharmaceutical Research, 2015
- Cardiac toxicity with anti-HER-2 therapies-what have we learned so far?Targeted Oncology, 2009